Dose response and atypical antipsychotics in schizophrenia

CNS Drugs
Bruce J KinonPeter F Buckley

Abstract

Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose related. The overlapping nature of these dose-response profiles limits the use of these agents. Atypical antipsychotics provide greater relief across the comorbid symptom domains of schizophrenia, but dose-response studies and clinical experience have revealed that some of these drugs also have dose limitations. This article reviews the dose-response relationships of the atypical antipsychotics as presented predominantly in pivotal, randomised studies (double-blind and otherwise). Limited data indicate that clozapine shows dose-related efficacy up to 600 mg/day in patients with treatment-resistant schizophrenia. However, higher dosages of clozapine may be associated with the risk of seizures. Risperidone demonstrates dose-related adverse events that compromise efficacy. The dose-response relationships for ziprasidone, quetiapine and aripiprazole are less well established. The efficacy of olanzapine appears to be dose related within the recommended dosage range of 10-20 mg/day, but clinical trials that have explored higher dosages suggest improved efficacy. Furthermore, the hi...Continue Reading

References

Dec 1, 1976·Archives of General Psychiatry·H A McClellandA A Schiff
Jul 1, 1978·Archives of General Psychiatry·J Endicott, R L Spitzer
Feb 1, 1991·Archives of General Psychiatry·A RifkinM Wachspress
Aug 1, 1990·Archives of General Psychiatry·T Van PuttenJ Mintz
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
Jun 1, 1987·Archives of General Psychiatry·S R MarderP R May
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Aug 1, 1982·The Journal of Nervous and Mental Disease·A M GhadirianL Annable
Aug 1, 1983·Archives of General Psychiatry·J M KaneJ Ramos-Lorenzi
Nov 1, 1984·Archives of General Psychiatry·S R MarderP R May
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Jan 4, 1996·The New England Journal of Medicine·J M Kane
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Feb 1, 1994·Psychopharmacology·A A MegensJ E Leysen
Jan 1, 1994·Drugs·S Kazda
Aug 1, 1995·The American Journal of Psychiatry·C K StoneJ Bennett
May 1, 1995·The American Journal of Psychiatry·D F LevinsonM J Stephanos
Jan 1, 1993·Psychopharmacology·C F Saller, A I Salama
Dec 1, 1994·Neurology·S V Pacia, O Devinsky
Sep 1, 1995·Psychosomatic Medicine·U HalbreichR Rosan
Jun 1, 1996·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·D D Miller
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Jan 1, 1996·Schizophrenia Bulletin·U Halbreich, S Palter
Dec 1, 1996·The American Journal of Psychiatry·C VanderZwaagT B Cooper
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M BeasleyJ N Beuzen
Aug 1, 1997·Journal of Clinical Psychopharmacology·L C KopalaW G Honer
Sep 1, 1997·The American Journal of Psychiatry·R R ConleyC A Tamminga
Feb 6, 1999·Journal of Clinical Psychopharmacology·D L KleinbergM Brecher
Apr 6, 1999·Schizophrenia Research·R A Dickson, W M Glazer
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan

❮ Previous
Next ❯

Citations

Oct 6, 2000·General Hospital Psychiatry·M A Adler Cohen, J M Jacobson
Aug 11, 2007·Cognitive Neuropsychiatry·Christian G KohlerRuben C Gur
Oct 13, 2009·Clinical Neuropharmacology·Rishikesh V BehereBangalore N Gangadhar
Aug 11, 2007·International Clinical Psychopharmacology·A Carlo AltamuraHerbert Y Meltzer
Aug 30, 2012·Journal of Personality Disorders·Eran ChemerinskiLarry J Siever
Dec 3, 2011·Journal of Neurosurgery. Pediatrics·Cristina V TorresJames T Rutka
Nov 24, 2004·Journal of Psychiatric Practice·Sheldon H Preskorn
Oct 4, 2011·The Journal of Nervous and Mental Disease·Peter F Buckley
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Dec 2, 2009·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Esam Bakir
Aug 28, 2007·The Psychiatric Clinics of North America·Helio Elkis
Mar 19, 2008·Basic & Clinical Pharmacology & Toxicology·Stig Ejdrup AndersenCharlotte Manniche
May 25, 2016·The Psychiatric Clinics of North America·Helio Elkis, Peter F Buckley
Oct 4, 2005·Expert Opinion on Pharmacotherapy·Peter F Buckley
Feb 14, 2012·Pharmaceutical Development and Technology·Magdi M Abdel HamidAdel A Sakr
Jul 27, 2010·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Nov 23, 2006·The Annals of Pharmacotherapy·Benjamin Chavez, Rene A Poveda
Oct 6, 2005·Journal of Psychopharmacology·Frank-Gerald B PajonkMarko Alexander Seelig
Feb 22, 2007·The Annals of Pharmacotherapy·Tawny L BettingerJames P Wilson
May 12, 2018·The Cochrane Database of Systematic Reviews·Myrto T SamaraStefan Leucht
May 12, 2018·The Cochrane Database of Systematic Reviews·Myrto T SamaraStefan Leucht
Oct 12, 2004·CNS Spectrums·Darius K Shayegan, Stephen M Stahl
Apr 15, 2014·British Journal of Hospital Medicine·James P Pandarakalam
Jan 9, 2021·Behavioural Brain Research·Kazunari Yoshida, Hiroyoshi Takeuchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here